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Abstract
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Background: The existing treatment options for men with intermediate- or high-volume
low-risk prostate cancer (PCa) are associated with a substantial risk of over- or
undertreatment. The development of risk-adjusted therapies is an unmet need for these
patients.
Objective: To describe our novel technique of precision prostatectomy, a form of surgical
focal therapy that allows radical excision of the index PCa lesion along with >90% prostatic tissue extirpation while preserving the prostatic capsule and seminal vesicle/vas
deferens complex on the side contralateral to the dominant cancer lesion, and to report
on medium-term functional and oncologic outcomes in the first 88 consecutive men
who underwent this procedure between December 2016 and January 2020.
Design, setting, and participants: Men with (1) prostate-specific antigen (PSA) 20 ng/
ml, (2) clinical T stage cT2, (3) a dominant unilateral lesion with Gleason  4 + 3 disease with any number or percentage of cores involved ipsilaterally on prostate biopsy,
(4) no primary Gleason 4 lesion contralaterally, and (5) a preoperative Sexual Health
Inventory of Men (SHIM) score of 17 (out of 25) with/without phosphodiesterase
type-5 inhibitor use who consented to undergo precision prostatectomy were included
in this single-arm, single-center, IDEAL stage 2b prospective development study.
Intervention: Robotic precision prostatectomy.
Outcome measurements and statistical analysis: The safety and urinary, sexual, and
oncologic outcomes of the precision prostatectomy technique were studied.
Descriptive statistics and Kaplan-Meier analyses were used to assess 12-mo urinary continence (0–1 pad), 12-mo sexual potency (SHIM score 17), 36-mo freedom from clinically significant PCa (grade group 2), secondary treatments, metastatic disease, and
mortality.
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Results and limitations: At study entry, the median age, PSA, and SHIM score were 60.0
yr (interquartile range [IQR] 54.2–65.9), 5.7 ng/ml (IQR 4.2–7.1), and 22 points (IQR 19–
24), respectively. The median follow-up was 25 mo (IQR 14–38). At 12 mo, all patients
were continent (0–1 pads), with 90.9% of patients using 0 pads. The median time to urinary continence was 1 mo (IQR 1–4). At 12 mo, 85% of all-comers and 90.2% of the preoperatively potent men were potent. The median time to sexual potency was 4 mo (IQR
4–12). From an oncologic standpoint, at 36 mo an estimated 93.4% of the patients were
free from clinically significant residual PCa and 91.7% had not undergone any additional
treatment. All patients were alive and free of metastatic disease at 36 mo.
Conclusions: Precision prostatectomy is technically safe and reproducible and offers
excellent postoperative functional results. At 36-mo follow-up, the oncologic outcomes
and secondary treatment rates appear to be superior to existing ablative focal therapy
results. Pending long-term data, a risk-stratified surgical approach to PCa may avoid
whole-gland therapy and preserve functional quality of life in men with localized PCa.
Patient summary: Precision prostatectomy is a new form of focal therapy for
intermediate-risk prostate cancer in which a 5–10-mm rim of prostate capsule is left
on the opposite side of the gland to where the dominant cancer is located. The technique
appears to be safe and efficacious and adds to the growing armamentarium of riskadapted therapies for treatment of localized prostate cancer that avoid the adverse
effects on urinary and erectile function of whole-gland treatments.
Ó 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

1. Introduction
Up to 50% of men diagnosed with prostate cancer (PCa) harbor clinically localized intermediate-risk disease (Gleason
score 3 + 4 or 4 + 3) at the time of initial diagnosis [1–3].
Similarly, 10% of new cases are high-volume low-risk
PCa cases. These men are typically managed with wholegland treatments such as radical prostatectomy (RP) or radiation therapy [4]. While whole-gland therapies provide durable oncologic control [5–12], owing to the proximity of the
prostate to vital neurovascular and fibromuscular structures in the pelvis [13–15], these treatments cause impotence in 50–70%, incontinence in 5–20%, and rectal
toxicity in 5–20% of cases [16–19]. These functional toxicities directly impact the quality of life of patients and their
partners [20]. According to current thinking, overtreatment
of clinically indolent PCa is a serious problem [21,22].
In efforts to avoid the side effects of whole-gland therapies, there has been a move towards the use of active
surveillance for patients with low-risk and favorable
intermediate-risk PCa. While active surveillance achieves
excellent functional outcomes [17], 40% of men require
radical treatment within 10 yr from treatment initiation
[9,23–26]. Furthermore, while active surveillance provides
acceptable long-term oncologic results in low risk PCa
patients, among patients with intermediate-risk disease
the risk of metastasis is quite high, at between 9% and
18% at 10–15 yr [26]. These figures highlight the problem
of undertreatment for men with intermediate-risk PCa.
Finally, in the long run active surveillance is a costly proposition [27].
In light of these data, there is a need for the development
of intermediary ‘‘risk-stratified’’ approaches to PCa treatment akin to those used in the management of several other
cancers such as breast, colon and rectum, kidney, and bladder cancer [28–31], for which there are options for organpreserving surgery.

Focal therapy (FT) of the PCa index lesion [32,33] seems
to offer one possible solution [34–38]. Accordingly, ablative
FT techniques have been shown to provide robust urinary
(95%) and sexual (85%) functional recovery after treatment. This treatment paradigm, however, has been associated with a high rate of oncologic failure, with
approximately 40% of patients harboring clinically significant residual PCa after initial treatment and 25% requiring
an additional treatment within 36 mo [34–40].
In an effort to improve on the oncologic drawbacks of
existing ablative FT techniques and active surveillance (undertreatment) and the functional shortcomings of radical
therapies (overtreatment), we developed a novel surgical
technique for subtotal resection of the prostate, called precision prostatectomy [41–43]. This technique allows maximal prostatic tissue extirpation (>90% tissue is removed)
without affecting the functional reserve [41–44]. Here we
provide a technical description of this novel surgical procedure and report on functional and oncologic outcomes in a
cohort of 88 men who underwent this procedure as part
of an IDEAL (Idea, Development, Exploration, Assessment
and Long-term Follow-up) stage 1–2b prospective development study.
2. Patients and methods
2.1.

Study entry criteria

The study cohort included men who participated in two separate
research protocols based on the IDEAL framework for surgical innovation
(IDEAL stage 1, n = 8; and IDEAL stage 2a–b, n = 101) [45–47]. Men with a
keen interest in preserving their sexual activity and who met the following criteria were considered eligible for the IDEAL stage 1 protocol: (1)
prostate-specific antigen (PSA) 15 ng/ml; (2) clinical T stage cT2;
(3) dominant unilateral lesion with Gleason  4 + 3 disease with any
number or percentage of cores involved ipsilaterally on prostate biopsy;
(4) no primary Gleason 4 lesion contralaterally; and (5) a preoperative
Sexual Health Inventory of Men (SHIM) score of 17 (out of 25) with/
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without phosphodiesterase type-5 inhibitor (PDE5i) use [41] (Fig. 1).

Portability and Accountability Act regulations using the Michigan Uro-

Patients were excluded from the study if they (1) had used androgen

logical Surgery Improvement Collaborative patient-reported outcomes

suppression within the previous 6 mo; (2) had undergone previous radi-

(MUSIC PRO) web portal [48], telephone interviews, and in-person visits.

ation therapy or chemotherapy for PCa; (3) had undergone previous

Data were collected at 1, 3–4, 8–9, 12–14, and 18–24 mo. All patients

high-intensity focused ultrasound (HIFU), cryosurgery, or thermal or

were followed for a minimum of 10 mo.

microwave therapy of the prostate; (4) were deemed unfit for general

Written informed consent was obtained from all study participants.

anesthesia; and (5) had life expectancy of <5 yr. These criteria were

Patients were apprised of the experimental nature of the intervention

based on prior studies of ablative FT techniques [34–40]. It is important

and the fact that the risks could not be accurately estimated given the

to note that no patients were excluded on the basis of prostate size or on

novelty of the procedure. Patients were required to review the informa-

anterior or apical location of the cancer. Following successful completion

tional material at least 7 d before consenting to surgery [42]. Failing this

of the IDEAL stage 1 study, the inclusion criteria for undergoing precision

in-home evaluation, patients were assigned to conventional RP or radia-

prostatectomy as part of the IDEAL stage 2a–b studies were expanded to

tion therapy.

include (1) men with PSA >15 ng/ml but 20 ng/ml to account for all
men with clinical intermediate-risk disease and (2) patients who were
preoperatively impotent but placed a high emphasis on preservation of

2.3.

Surgical technique

their baseline function status (further details in Fig. 1). In addition, as

Patient positioning, port placement, development of the space of Retzius,

the procedure matured (following participant no. 51 of the 109 screened

bladder neck incision, and prostatic pedicle dissection were all per-

patients) all patients under consideration for study enrollment were

formed in a manner similar to the traditional anterior approach for

asked to undergo a transperineal biopsy using the KOELIS Trinity plat-

robotic RP [49,50]. The difference was in the way the nerve-sparing

form (Grenoble, France) targeting the capsule and peripheral zone of

was performed. On the side of the dominant cancer lesion, conventional

the prostate that we intended to leave behind (Fig. 1 in reference

nerve-sparing was undertaken, while on the contralateral side (the pre-

[42]). This criterion was added to minimize potential undertreatment,

cision side) the dissection was started anterior to the vas deferens/sem-

and patients with any cancer on this biopsy were excluded.

inal vesicle complex, preserving all the layers of Denonvilliers’ fascia,
including the erectogenic nerves [13,14]. The dissection was then con-

2.2.

Study design, data collection, and informed consent

tinued 5–10 mm into the prostatic capsule/peripheral tissue (Fig. 2A),
deliberately leaving behind a thin rim of this tissue (5–10 mm) along

The current investigation was a single-arm, single-center IDEAL stage 1–

with the seminal vesicle/ejaculatory duct complex (Fig. 2B,C) [41,42].

2b prospective development study [45–47] and followed our IDEAL stage

The approach allows >90% prostatic tissue extirpation with in toto

0 (preclinical) and 1 (early clinical) studies that laid the theoretical foun-

preservation of the neurovascular tissue on the side contralateral to

dation for precision prostatectomy and established its feasibility, respec-

the dominant lesion. Intraoperative systematic needle biopsies (via a

tively [41,42]. Data collection was carried out under ongoing research

suprapubic or transperineal approach) were taken from the remnant

protocols approved by the Henry Ford Hospital institutional review

prostatic tissue and sent for frozen section analysis. Completion of

board (HFH-IRB#12507 for IDEAL stage 1 and HFH-IRB#14531 for IDEAL

prostatectomy through the prerectal fossa was performed if the frozen

stage 2a–b). Data were collected in compliance with Health Insurance

biopsies showed residual cancer. Vesicourethral anastomosis was per-

Fig. 1 – Study design and entry criteria for patients undergoing robotic precision prostatectomy. *Of the 88 patients included in the study, eight were part of
the IDEAL stage 1 study and accordingly were enrolled according to the initial selection criteria (HFH-IRB#12507), while the next 80 patients were enrolled
into IDEAL stage 2a–b studies according to the expanded criteria (HFH-IRB#14531). Of the 80 IDEAL stage 2a–b patients, two had PSA >15 ng/ml and ten were
preoperatively impotent. EPE = extraprostatic extension; PP = precision prostatectomy; PSA = prostate-specific antigen; RP = radical prostatectomy;
SHIM = Sexual Health Inventory for Men.
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Fig. 2 – (A) Histologic micrograph of a prostate gland stained with hematoxylin and eosin demonstrating the prostatic capsule and glands. (B) Illustration of
an excised prostate specimen and of (C) the remnant in the prostatic fossa during precision prostatectomy.

formed as previously described [49,50]. A Foley catheter or suprapubic

ber of positive cores on biopsy, locations of positive biopsy cores, and

tube was inserted according to patient choice [51]. The accompanying

pre- and post-treatment functional status according to the International

surgical video and animation illustrate the surgical technique in

Prostate Symptom Score (IPSS), urinary pad usage, and the International

detail.

Index of Erectile Function-5 or SHIM questionnaire. Urinary continence

2.4.

Covariates and endpoints

was defined as use of 0–1 pad per day, and potency was defined as a
SHIM score 17. The operative characteristics collected included total

For each patient, the following clinical characteristics were recorded:

operative time, console operative time, estimated blood loss, results

age, race, body mass index, comorbidities, preoperative PSA level, clini-

for frozen section analysis, intraoperative complications, and need to

cal T stage, biopsy Gleason score, total number of cores on biopsy, num-

convert to RP. Pathologic parameters collected included pathologic Glea-
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son score, pathologic tumor stage, and surgical margin status. Postoper-

criteria for biochemical failure following RP (ie, a single PSA value of

atively, patients were monitored for the development of procedure-

0.4 ng/ml or two consecutive values 0.2 ng/ml) [52]; (2) the Phoenix

related complications. Complications noted included need for blood

criterion for radiation therapy [53]; and (3) the Huber criterion for FT

transfusion, urinary tract infection, lymphocele, deep vein thrombosis,

[54]. Patients with evidence of biochemical failure according to any of

pulmonary embolus, pneumonia, myocardial infarction, and death in

these criteria underwent remnant biopsy confirmation (Supplementary

the 90 d after surgery. With regard to oncologic assessment, three sepa-

Table 1). Remnant biopsy confirmation was conducted because detect-

rate criteria were used to define treatment failure according to postop-

able PSA could be the result of residual benign tissue or malignant cells,

erative PSA levels: (1) the American Urological Association (AUA)

and histologic verification was required to diagnose biochemical failure
of cancer control. Additional oncologic and survival endpoints assessed
included clinically significant residual PCa (International Society of Urological Pathology grade group 2) in the remnant, metastasis, cancer-

Table 1 – Baseline demographic and clinical characteristics of 88
patients treated with robotic precision prostatectomy
Parameter
Patient characteristics
Median age, yr (interquartile range)
Race, n (%)
Caucasian
African American
Other
Median body mass index, kg/m2 (interquartile
range)
Past medical history, n (%)
Hypertension
Diabetes mellitus
Coronary artery or cerebrovascular disease
Smoker, n (%)
Past surgical history, n (%) a
Prostate cancer characteristics
Median prostate-specific antigen, ng/ml
(interquartile range)
Prostate-specific antigen category, n (%)
<10 ng/ml
10–20 ng/ml
>20 ng/ml
Median number of biopsy cores obtained, n
(interquartile range) b
Biopsy Gleason score, n (%)
3+3
3+4
4+3
4+4
Laterality of disease on biopsy, n (%)
Unilateral
Bilateral
Clinical stage, n (%)
cT2a
cT2b
cT2c
Patients who underwent a dedicated KOELIS threedimensional biopsy, n (%) c
Patients satisfying the Epstein criteria for active
surveillance, n (%) d
Median estimated prostate size, g (interquartile
range)
Functional characteristics
Median SHIM score (interquartile range)
SHIM score category, n (%)
<17
17–21
22
Patients on a phosphodiesterase type-5 inhibitor, n
(%)
Median IPSS composite score (interquartile range)
Median IPSS QoL score (interquartile range)

Result
60.0 (54.2–65.9)
61 (69.3)
20 (22.7)
7 (8.0)
28.0 (25.2–30.1)

specific mortality, and overall mortality.

2.5.

Statistical analyses

Descriptive statistics for categorical variables included the frequency
and proportion. The median and interquartile range (IQR) were used
for continuous variables. Kaplan-Meir analyses were performed to assess
freedom from biochemical failure, clinically significant PCa (ISUP grade
group 2) in the prostate remnant, secondary treatment, metastatic progression, cancer-specific mortality, and overall mortality. The log-rank

47 (53.4)
4 (4.5)
36 (40.9)
8 (9.1)
39 (44.3)

Table 2 – Operative and immediate postoperative characteristics of
88 patients treated with robotic precision prostatectomy
Parameter

5.7 (4.2–7.1)

Operative characteristics
Median operative time, min (interquartile range)
Median console time, min (interquartile range)
Median estimated blood loss, ml (interquartile range)
Precision prostatectomy laterality, n (%)
Left
Right
Type of nerve sparing on the radical side, n (%)
Veil (intrafascial)
Standard (interfascial)
Wide (extrafascial)
Intraoperative capsular biopsy details
Biopsy performed, n (%)
Median number of biopsy cores taken, n (interquartile
range)
Approach, n (%)
Suprapubic approach
Robotic scissors approach
Transrectal approach
Transperineal approach
Not applicable (biopsy not performed)
Intraoperative biopsy results, n (%) a
Atypia
Benign prostatic hyperplasia
Fibromuscular tissue
Not applicable (biopsy not performed)
Median number of lymph nodes removed, n
(interquartile range) b
Immediate postoperative outcomes
Median length of stay, d (interquartile range)
Inpatient complications, n (%) c
Complications within 3 mo, n (%) c

83 (94.3)
5 (5.7)
0 (0)
14 (12–16)

20 (22.7)
54 (61.4)
14 (15.9)
0 (0)
56 (63.6)
32 (36.4)
86 (96.7)
1 (1.1)
2 (2.2)
39 (44.3)
4 (4.5)
46.8 (37–69.5)

22 (19–24)
10
26
52
20

(11.4)
(29.5)
(59.1)
(22.7)
a

4.5 (2–10)
1 (0–2)

SHIM = Sexual Health Inventory for Men; IPSS = International Prostate
Symptom Score; QoL = quality of life.
a
Past surgeries recorded included colectomy, splenectomy, umbilical
or inguinal hernia repair, cholecystectomy, and appendectomy.
b
Initial biopsies were performed transrectally with/without magnetic
resonance imaging fusion (n = 81) or transperineally using KOELIS
ultrasound (n = 7).
c
Seven patients had a KOELIS ultrasound biopsy as their initial biopsy,
while 32 had a confirmation KOELIS ultrasound biopsy.
d
Patients chose to have precision prostatectomy (focal therapy).

b
c

Result
169 (147–191)
130 (110–142)
100 (75–125)
41 (46.6)
47 (53.4)
36 (40.9)
51 (58.0)
1 (1.1)
68 (77.3)
7 (4–9)

42 (47.7)
15 (17.1)
1 (1.1)
10 (11.4)
20 (22.7)
7 (7.9)
59 (67.1)
2 (2.3)
20 (22.7)
8 (4–14)

1 (1-1)
0 (0)
5 (5.7)

Patients who had a positive result on intraoperative biopsy were converted
to standard radical prostatectomy (n = 3 of the 91 patients who underwent
attempted precision prostatectomy).
Twelve patients did not have lymph nodes removed.
Complications captured were acute blood loss anemia, urinary tract
infection, epididymitis, surgical site infection, wound dehiscence, deep vein
thrombosis/pulmonary embolism, myocardial infarction, pneumonia,
lymphocele and return to the operating room for any reason; the five
patients who experienced complications included two lymphoceles
requiring interventional radiology-guided drainage, one urinary tract
infection (outpatient antibiotic treatment), one skin reaction to adhesive
tape (observation and referral to dermatology), and one epididymitis
(outpatient antibiotic treatment).
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test was used to compare oncologic outcomes for patients with and

3.2.

Functional outcomes

without positive surgical margins. Statistical analyses were performed
using the R statistical package (R Foundation for Statistical Computing,
Vienna, Austria), with two-sided p values <0.05 considered statistically
significant.

3. Results
3.1.
Study population, baseline characteristics, and
operative outcomes

Between December 2016 and January 2020, 109 patients
met the study entry criteria and were interested in undergoing the precision prostatectomy procedure. Eighteen
patients (16.5%) were excluded before surgery on the basis
of results for a pre-enrollment transperineal prostate biopsy
(Fig. 1). A total of 91 men ultimately underwent the precision prostatectomy procedure; however, positive intraoperative biopsies of the remnant tissue led to conversion to RP
in three cases. Table 1 lists baseline characteristics for the
88 men for whom the precision prostatectomy procedure
was successfully completed. The median age and PSA for
this group were 60.0 yr (IQR 54.2–65.9) and 5.7 ng/ml
(IQR 4.2–7.1), respectively. All patients were continent preoperatively, and 88.6% were potent (SHIM score 17), with
20 patients (22.7%) using PDE5i. Four of the 88 patients
(4.5%) met the Epstein criteria [55] for active surveillance
but chose to undergo precision prostatectomy for personal
preference.
The median console time was 130 min (IQR 110–142).
There were no complications intraoperatively, but five
patients (5.7%) experienced a complication postoperatively.
Two complications were Clavien-Dindo grade IIIa and the
remaining three were grade II (Table 2).

At 12 mo, 100% of the patients were continent (0–1 pads),
with 90.9% using 0 pads (Fig. 3A). The median time to urinary continence was 1 mo (IQR 1–4). Some 85% of allcomers and 90.2% of the preoperatively potent patients
were potent at 12 mo (Fig. 3B). The median SHIM score
was 21 at 12 mo. At this time point, 76.4% of patients were
using PDE5i on an as-needed basis. The median time to sexual potency recovery was 4 mo (IQR 4–12).
3.3.

Oncologic outcomes

Table 3 provides details for the oncologic and survival outcomes. The median follow-up was 25 mo (IQR 14–38).
Among the 88 patients treated, median postoperative PSA
was 0.0 ng/ml at 12-mo and 24-mo follow-up. We used
three separate criteria to assess biochemical failure (as
noted above) given the novelty of our technique and lack
of societal guidelines regarding oncologic follow-up for FT
patients. Two patients (2.8%) had biochemical failure
according to the Phoenix or Huber criterion. Using the more
stringent AUA post-RP criterion, 25 patients had biochemical failure (36-mo Kaplan-Meier estimate for biochemical
failure: 41.9%); however, the detectable PSA was due to
PCa in only ten patients, as detected on biopsy of the remnant (36-mo Kaplan-Meier ‘‘corrected’’ estimate for biochemical failure: 16.3%; Table 3). In the remaining 15
patients, PSA was detectable due to residual benign prostatic tissue (a median of 8 [IQR 4–9] biopsy cores were
obtained from the remnant tissue). Of the ten patients
who had PCa, five had Gleason 3 + 3 = 6, two had Gleason
3 + 4 = 7, one had Gleason 4 + 3 = 7, and two had Gleason
 4 + 4 = 8 disease in the remnant. All five patients with
clinically significant PCa and one with Gleason 3 + 3 = 6 dis-

Fig. 3 – (A) Urinary continence (using two definitions: 0 pad or 0–1 pad), and (B) sexual potency (defined as SHIM 17 in all-comers or preoperatively potent)
recovery rates over a 24-mo period for patients treated with precision prostatectomy. n = number of patients evaluated at a particular time point;
ICI = intercavernosal injection; PDE5i = phosphodiesterase type-5 inhibitor; SHIM = Sexual Health Inventory for Men.
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Table 3 – Pathologic and medium-term oncologic outcomes for 88
patients treated with robotic precision prostatectomy
Parameter
Pathologic outcomes
Median prostate weight, g (interquartile range)
Pathologic T stage, n (%)
pT2a
pT2b
pT2c
pT3a
pT3b
Pathologic N stage, n (%)
pN0
pN1
pNx
Pathologic Gleason score, n (%)
3+3
3+4
4+3
4+4
Surgical margin details
Positive status, n (%) a
Positive on precision prostatectomy side
Positive on radical side
Positive on both sides
Positive margin focality, n (%) b
Focal 3 mm
Nonfocal >3 mm
Gleason score at margin, n (%)
3+3
3+4
4+3
4+4
Medium-term oncologic outcomes
Median prostate-specific antigen, ng/ml
(interquartile range) c
At 12 mo
At 24 mo
Freedom from biochemical failure according to
FT/RT criteria at 36 mo d,e,f
Phoenix criterion, % (95% CI)
Huber criterion, % (95% CI)
Freedom from prostate cancer in the remnant
at 36 mo d,f
Any cancer, % (95% CI)
Clinically significant cancer, % (95% CI)
Freedom from secondary treatment at 36 mo, %
(95% CI) f
Metastatic disease at 36 mo, % (95% CI) f
Cancer-specific mortality at 36 mo, % (95% CI) f
Overall mortality at 36 mo, % (95% CI) f

Result
40 (30–55.5)
6 (6.8)
11 (12.5)
47 (53.4)
18 (20.5)
6 (6.8)
74 (84.1)
2 (2.3)
12 (13.6)
9 (10.2)
63 (71.6)
13 (14.8)
3 (3.4)

11 (12.5)
16 (18.2)
10 (11.4)
20 (22.7)
17 (19.3)
21 (23.8)
11 (12.5)
4 (4.6)
1 (1.1)

0.0 (0.0–0.30)
0.0 (0.0–0.30)

97.2 (95.1–99.3)
97.2 (95.1–99.3)

83.7 (79.1–88.4)
93.4 (90.2–96.6)
90.7 (86.8–94.6)
0 (0)
0 (0)
0 (0)

CI = confidence interval; FT = focal therapy; RT = radiation therapy.
a
Of the 11 positive surgical margins on the precision prostatectomy
side, seven were Gleason 3 + 3 and four were Gleason 3 + 4; of the 16
positive surgical margins on the radical side, nine were Gleason 3 + 3,
four were Gleason 3 + 4, two were Gleason 4 + 3, and one was Gleason
4 + 5; and of the ten positive surgical margins on both sides, five were
Gleason 3 + 3, three were Gleason 3 + 4, and two were Gleason 4 + 3.
b
Of the 11 positive surgical margins on the precision prostatectomy
side, seven were focal and four were nonfocal; of the 16 positive
surgical margins on the radical side, 13 were focal and three were
nonfocal; and all ten of the positive surgical margins on both sides
were nonfocal.
c
Data mature for 79 patients for 1 yr and 59 patients for 2 yr.
d
Data mature for 72 patients at 12–18 mo when protocol biopsies are
performed.
e
Phoenix criterion has been defined as nadir +2 ng/ml and Huber
criterion as nadir +1.5 ng/ml at 2–3 yr for patients undergoing focal
therapy.
f
Kaplan-Meier estimate with 95% CI.

ease had remnant removal surgery (36-mo Kaplan-Meier
estimate for secondary therapy: 9.3%; Fig. 4), while the
other four (all with Gleason 3 + 3 = 6 disease) chose active
surveillance. The six patients who underwent remnant
removal have had undetectable PSA at median follow-up

7

of 10.2 mo, with two also receiving adjuvant radiation therapy in accordance with the standard treatment protocol. All
patients were alive and free of metastatic disease at the
time of last follow-up (Table 3).
Surgical margin status was not associated with biochemical failure (log-rank p = 0.275), the presence of clinically
significant residual PCa (log-rank p = 0.805), or a need for
secondary therapy (log-rank p = 0.850). Fig. 5 shows details
of the correlation of surgical margin status with biochemical failure, the presence of clinically significant residual
PCa, and a need for secondary treatment.
3.4.
Operative, functional, and cancer outcomes in six men
who required remnant removal

For the six men who underwent remnant removal, the median console time was 59 min (IQR 48–85), inclusive of pelvic
lymphadenectomy when undertaken. The median estimated blood loss was 25 ml. All patients were discharged
home from the recovery unit on postoperative day 0. Two
of the six patients (33.3%) required Foley catheterization
for 2 d, while the others were discharged without a catheter. All patients remained continent postoperatively, albeit
with complete loss of potency. With regard to oncologic
outcomes, as stated above, all six patients were free from
biochemical failure after remnant removal at median
follow-up of 10.2 mo, with two patients receiving adjuvant
radiation therapy. All six patients were free of metastatic
disease and alive at their last follow-up. The findings on
final pathology for these patients are detailed in Supplementary Table 2.
4. Discussion
One reason for the historic reluctance to treat PCa with focal
approaches is the multifocal nature of the disease [56].
However, this issue can now largely be solved using sophisticated pretreatment biopsy methods guided by multiparametric magnetic resonance imaging (mpMRI) or other
molecular imaging modalities that allow careful mapping
of cancer foci within the prostate. As a result of these
advances in imaging and biopsy techniques, focal ablation
using a host of ablative technologies has been exhaustively
trialed in the last decade [57]. While functional outcomes
have been encouraging, oncologic outcomes have been less
so, with studies demonstrating residual cancer in up to 40%
of treated patients (any cancer in close to 60% of patients),
necessitating secondary therapy in 25% of patients within
3 yr of their initial treatment (Table 4).
We reasoned that the high oncologic failure rate after
focal ablation is related to three co-existing issues: (1) the
presence of lesions containing clinically significant PCa
below the detection resolution of existing mpMRI technology (currently 10 mm in diameter or 0.5 cm3 in volume)
[58]; (2) the existence of tumor multifocality [56] and field
cancerization [59]; and (3) an inability or reluctance to
ablate >60% of the gland as well as apical or anterior
cancers.
We performed an IDEAL stage 0 mapping study [41] of
whole-mount specimens from surgically removed PCa from
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Fig. 4 – Kaplan-Meier analysis of freedom from (A) post-treatment clinically significant prostate cancer (PCa) and (B) secondary treatment in patients treated
with precision prostatectomy. CI = confidence interval.

Fig. 5 – Flowchart stratifying oncologic outcomes by surgical margin status to assess the association of surgical margin positivity with biochemical failure,
clinically significant residual disease in the remnant, and a need for secondary therapy in patients treated with precision prostatectomy (PP). * Log-rank p
values determined via Kaplan-Meier analysis. 3D = three-dimensional; AUA = American Urological Association; BCR = biochemical recurrence; PCa = prostate
cancer; TRUS = transrectal ultrasound.

patients who met criteria for FT but underwent RP to test
these assumptions. We simulated focal and hemigland HIFU
for these patients and found that if they had been treated
with focal ablation, 71% would have had clinically significant PCa in the unablated peripheral zone given that focal
HIFU spares 5–10 mm of peripheral tissue on the treatment
side and does not treat the contralateral side. With hemiablation, 21% would have had clinically significant cancer left
behind. Similar findings have been reported by Kenigsberg
et al [60]. In a simulation study of partial-gland HIFU using
RP specimens from patients meeting criteria for FT, the
authors noted that significant PCa (Gleason 4) would have
been left behind in 23.7% of patients [60].

On the basis of data generated in the stage 0 study and a
review of literature, we posited that the key to overcoming
the aforementioned drawbacks of existing FT modalities is
to maximize prostatic tissue extirpation without affecting
functional reserve [44]. We therefore contemplated the
development of a surgical procedure that would minimize
the risks of overtreatment and undertreatment. With our
novel surgical approach, all prostatic tissue is resected
except for a 5–10-mm rim of prostate capsule/peripheral
zone on the side contralateral to the dominant lesion,
resulting in removal of >90% of the prostatic tissue [41].
We showed that after this surgical procedure, patients
experience a robust functional recovery with an acceptable
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Table 4 – Literature review of key focal therapy series that provided detailed data on postoperative oncologic outcomes
Study

Year

N

HIFU

Post-HIFU Bx

template

Bx
cohort,

Bx indication

n (%)
Abreu

2020

100

HG

58 (58)

Mortezavi

2019

75

F

Bass

2018

150

PG

Rischmann

2017

111

HG

Van Velthoven

2016

50

Feijoo

2016

67

Ahmed

2015

56

HG ±
TURP
HG ±
TURP
F

68
(90.6)
87
(58.0)
101
(90.9)
8 (16.0)

Shoji

2015

45

HG

2015

4

F

Ahmed

2012

41

F

Ahmed

2011

20

HG

El Fegoun

2011

12

HG

Ghai

g

e

67
(100)
52
(92.8)
45
(100)
4 (100)
39
(95.1)
19
(95.0)
12
(100)

Oncologic outcomes
Time

Bx
template

to Bx

Residual cancer, n/
N (%)
GS 7

Secondary

32/58
(55.2)
38/68
(55.9)
61/87
(70.1)
33/101
(32.7)
6/8 (75)

18/58
(31.0)
28/68
(41.2)
37/87
(42.5)
12/101
(11.9) d
6/8 (75)

17/89
(19.1)
12/68
(17.6)
37/150
(24.7)
18/101
(17.8)
NA

8/89 (9.0)

17/67
(25.4)
22/52
(42.3)
4/45
(9.0)
4/4
(100)
9/39
(23.1)
2/19
(10.5)
1/12
(8.3)

NA

NA

NA

10/52
(19.2)
NA

4/52 (7.8)

2/52 (3.8)

3/45 (6.7)

1/45 (2.2)

0

0

0

3/39 (7.7)

4/39 (10.3)

0

0

1/19 (5.3)

0

0

5/12 (41.6)

4/12
(33.3)

Any

Protocol or clinically
indicated b
Protocol

6–12 mo

WG

6 mo

WG

Protocol

15 mo

Protocol

1 yr

WG

Phoenix BCF

NA

WG

Protocol

<1 yr

WG

Protocol

6 mo

Protocol

6 mo

Protocol

6 mo

Treated or
MMSL
Limited
WG f
WG

Protocol

6 mo

Protocol

6 mo

Protocol or rising PSA

1 yr

c

WG

Treated or
MMSL
Treated or
MMSL
Limited
WG f

Treatment rate, n/N
(%)
Radical

a

6/68 (8.8)
20/150
(13.3)
15/101
(14.6) d
NA

Bx = biopsy; HIFU = high-intensity focused ultrasound; GS = Gleason score; HG = hemigland; F = focal; PG = partial gland; TURP = transurethral resection of the
prostate; BCF = biochemical failure; WG = whole gland; MMSL = multiparametric magnetic resonance imaging–suspicious lesions; NA = not applicable.
a
Secondary treatment rate includes radical treatment.
b
Clinically indicated on the basis of PSA, digital rectal examination, or multiparametric magnetic resonance imaging findings.
c
Mean time to Bx was 14.8 ± 7.6 mo.
d
Clinically significant prostate cancer was defined as GS 7 or cancer core length >3 mm regardless of grade or more than two positive cores; radical
treatment included six patients with radical prostatectomy, three with external beam radiotherapy (EBRT), two radical HIFU, and four with third-line
treatment, including one radical prostatectomy, two EBRT, and one androgen deprivation therapy.
e
Urethra-sparing HIFU.
f
Four to eight or six Bx samples were taken.
g
Only patients with Gleason 3 + 3 disease were included in the study.

risk of residual disease. More specifically, we found that
100% of the patients were continent and 90% of the preoperatively potent men were potent by 1 yr. The functional
recovery seen in these patients is not entirely surprising
given the results for other surgical procedures that preserve
the prostate capsule, such as partial prostate-sparing radical
cystectomy, simple prostatectomy, partial prostatectomy
for isolated anterior prostatic tumors, and holmium laser
enucleation of the prostate [44,61–63]. In terms of cancer
control, there is ongoing concern regarding the oncologic
efficacy of FT techniques. One concern is with the historically high rate of local treatment failure as evidenced by
post-treatment biopsy (Table 4). However, it is worth noting that it is not known whether this local failure will translate into higher rates of progression to metastatic disease or
eventual PCa-related death. Findings from a multicenter 5yr follow-up study of 505 men with primarily
intermediate-risk PCa who underwent focal HIFU appear
to be reassuring [64] -- the study reported cancer-specific
survival of 100%, but a retreatment rate of 27% within 36
mo and a positive biopsy rate of 25% among men who were
rebiopsied. It is important to note that in this multiinstitutional study not all patients underwent a biopsy,
and those who did, frequently only underwent an ‘‘infield’’ biopsy. A more recent single-institution study of
150 men (n = 132 with Gleason 7 disease) which evaluated

patients using whole-gland biopsies found residual cancer
in 70.1% of men and a retreatment rate of 25% within 12–
24 mo, despite an attempt to ablate five to ten times the
lesion volume detected on mpMRI [36]. Table 4 provides
details on additional HIFU studies that reported similar
rates of local oncologic failure. By comparison, during a
median follow-up of 25 mo, only 6.6% of the patients in
our current series had evidence of clinically significant
PCa on saturation biopsy of the remnant, and 9.3% had
undergone a secondary procedure. Thus during limited
follow-up, oncologic results for precision prostatectomy
appear to compare favorably to results for ablative forms
of FT, while the functional outcomes appear to be
equivalent.
Our study is not devoid of limitations within the bounds
of which our findings should be interpreted. First, we did
not routinely use mpMRI guidance or perform preoperative
3D ultrasound-guided biopsies of the planned remnant in
all patients to optimize selection of candidates for precision
prostatectomy. Although this is a drawback of our study, it
is an avenue for future improvement and we believe that
with a regimented, standardized image-guided preoperative assessment we will be able to reduce the rate of local
oncologic failure even further. Second, this is a single-arm,
single-center study that evaluated only a limited number
of patients. Third, the oncologic follow-up was relatively
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short at a median of 25 mo. In addition, the surgeries were
performed by only two surgeons (M.M. and W.J.), both of
whom have extensive experience in performing robotic surgery. Hence, caution is required in drawing conclusions
regarding this procedure. To expand the body of evidence
for this procedure, we have planned a randomized controlled trial (HFH-IRB #14603) comparing functional and
oncologic outcomes between precision prostatectomy and
the standardly performed RP procedure.
5. Conclusions
Whole-gland therapy for PCa provides excellent cancer control but results in high rates of erectile dysfunction and urinary incontinence. Focal ablative therapy eliminates sexual
dysfunction but at the cost of leaving residual cancer. We
propose a novel surgical approach—precision prostatectomy—that maximizes functional reserve while minimizing
cancer undertreatment. This procedure may defer or avoid
the need for immediate whole-gland therapy in a significant
proportion of men with clinically localized PCa who are in
need of or desire treatment. Longer follow-up and rigorous
investigation in randomized trials are necessary to properly
define the exact role of precision prostatectomy in the treatment of men with localized PCa.
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